Dr. Reddy's Laboratories announces the launch of Desmopressin Acetate Injection USP, 4 mcg/mL
in the U.S. Market
News Desk, News Nation 360: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories, told the launch of Desmopressin Injection demonstrates a strong, growing collaboration with SunGen Pharma. They look forward to future opportunities with this company. Isaac Liu, Ph.D., Co-CEO of SunGen, told they are pleased to be working with Dr. Reddy’s for this launch. The launch of Desmopressin demonstrates their strong development capabilities. They look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world. Dr. Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single-dose ampules.
Report : Anustup Kundu